标题
Prostate cancer
作者
关键词
-
出版物
LANCET
Volume 398, Issue 10305, Pages 1075-1090
出版商
Elsevier BV
发表日期
2021-08-07
DOI
10.1016/s0140-6736(21)00950-8
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
- (2021) Michael S Hofman et al. LANCET
- Prostate cancer
- (2021) Richard J. Rebello et al. Nature Reviews Disease Primers
- Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
- (2021) Oliver Sartor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort
- (2020) Jeffrey J. Tosoian et al. EUROPEAN UROLOGY
- Radiation Dose Escalation or Longer Androgen Suppression to Prevent Distant Progression in Men With Locally Advanced Prostate Cancer: 10-Year Data From the TROG 03.04 RADAR Trial
- (2020) David Joseph et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer
- (2020) Himisha Beltran et al. JOURNAL OF CLINICAL INVESTIGATION
- Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
- (2020) Matthias Guckenberger et al. LANCET ONCOLOGY
- Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials
- (2020) William C. Jackson et al. JOURNAL OF CLINICAL ONCOLOGY
- Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study
- (2020) Michael S Hofman et al. LANCET
- A genomic and epigenomic atlas of prostate cancer in Asian populations
- (2020) Jing Li et al. NATURE
- Olaparib for Metastatic Castration-Resistant Prostate Cancer
- (2020) Johann de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
- (2020) Cora N. Sternberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress
- (2020) Michael D. Nyquist et al. Cell Reports
- Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer
- (2020) Ryan Phillips et al. JAMA Oncology
- Bad neighbours: hypoxia and genomic instability in prostate cancer
- (2020) Jack Ashton et al. BRITISH JOURNAL OF RADIOLOGY
- Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
- (2020) David A. Palma et al. JOURNAL OF CLINICAL ONCOLOGY
- Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors
- (2020) Karim Fizazi et al. EUROPEAN UROLOGY
- Apalutamide and Overall Survival in Prostate Cancer
- (2020) Matthew R. Smith et al. EUROPEAN UROLOGY
- Newly Diagnosed High-Risk Prostate Cancer in an Era of Rapidly Evolving New Imaging: How Do We Treat?
- (2020) Maha Hussain et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data
- (2020) Claire L Vale et al. LANCET
- Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial
- (2020) Christopher C Parker et al. LANCET
- Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial
- (2020) Andrew Kneebone et al. LANCET ONCOLOGY
- Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial
- (2020) Paul Sargos et al. LANCET ONCOLOGY
- Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide
- (2020) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trends in Diagnosis and Disparities in Initial Management of High-Risk Prostate Cancer in the US
- (2020) Vishesh Agrawal et al. JAMA Network Open
- Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial
- (2020) Rafael E. de Feria Cardet et al. EUROPEAN UROLOGY
- TP53 and Prognosis in mCRPC Survival: Biology or Coincidence?
- (2019) Richard J. Rebello et al. CLINICAL CANCER RESEARCH
- Molecular landmarks of tumor hypoxia across cancer types
- (2019) Vinayak Bhandari et al. NATURE GENETICS
- The influence of BRCA2 mutation on localized prostate cancer
- (2019) Renea A. Taylor et al. Nature Reviews Urology
- Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Matthew Smith et al. LANCET ONCOLOGY
- Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial
- (2019) Bertrand Tombal et al. LANCET ONCOLOGY
- Defining Prostate Cancer at Favorable Intermediate Risk: the Potential Utility Of Magnetic Resonance Imaging And Genomic Tests.
- (2019) Ugo G Falagario et al. JOURNAL OF UROLOGY
- Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer
- (2019) James L. Gulley et al. JOURNAL OF CLINICAL ONCOLOGY
- Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer—Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis
- (2019) Marlon Perera et al. EUROPEAN UROLOGY
- Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2
- (2019) Baris Turkbey et al. EUROPEAN UROLOGY
- A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer
- (2019) Jonas Hugosson et al. EUROPEAN UROLOGY
- ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer
- (2019) Laura Cato et al. CANCER CELL
- Metastatic prostate cancer at diagnosis and through progression in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
- (2019) Paul F. Pinsky et al. CANCER
- Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019
- (2019) Giorgio Gandaglia et al. EUROPEAN UROLOGY
- Strategies for Evaluation of Novel Imaging in Prostate Cancer: Putting the Horse Back Before the Cart
- (2019) Neha Vapiwala et al. JOURNAL OF CLINICAL ONCOLOGY
- Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
- (2019) David A Palma et al. LANCET
- Genomic correlates of clinical outcome in advanced prostate cancer
- (2019) Wassim Abida et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Prostate Magnetic Resonance Imaging, with or Without Magnetic Resonance Imaging-targeted Biopsy, and Systematic Biopsy for Detecting Prostate Cancer: A Cochrane Systematic Review and Meta-analysis
- (2019) Frank-Jan H. Drost et al. EUROPEAN UROLOGY
- 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial
- (2019) Jeremie Calais et al. LANCET ONCOLOGY
- Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
- (2019) Ian D. Davis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
- (2019) Kim N. Chi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prostate-Specific Membrane Antigen Ligand Positron-Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer
- (2019) Wolfgang P Fendler et al. CLINICAL CANCER RESEARCH
- Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
- (2019) Ronald de Wit et al. NEW ENGLAND JOURNAL OF MEDICINE
- Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance
- (2019) Annika Herlemann et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
- (2019) N W Clarke et al. ANNALS OF ONCOLOGY
- Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
- (2019) Emmanuel S. Antonarakis et al. JOURNAL OF CLINICAL ONCOLOGY
- Prostate cancer incidence and mortality in the Baltic states, Belarus, the Russian Federation and Ukraine
- (2019) Ausvydas Patasius et al. BMJ Open
- Genomics of lethal prostate cancer at diagnosis and castration resistance
- (2019) Joaquin Mateo et al. JOURNAL OF CLINICAL INVESTIGATION
- Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline
- (2019) Scott E. Eggener et al. JOURNAL OF CLINICAL ONCOLOGY
- The MRI in Active Surveillance “MRIAS” Trial: Use of Baseline mpMRI and Saturation Biopsy to Reduce the Frequency of Surveillance Prostate Biopsies
- (2019) Amer Amin et al. JOURNAL OF UROLOGY
- The tip of the iceberg: predicting PARP inhibitor efficacy in prostate cancer
- (2019) Silke Gillessen et al. LANCET ONCOLOGY
- Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial
- (2019) Daniel J Khalaf et al. LANCET ONCOLOGY
- Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
- (2019) Joaquin Mateo et al. LANCET ONCOLOGY
- Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study
- (2018) A R Hansen et al. ANNALS OF ONCOLOGY
- National implementation of multi-parametric magnetic resonance imaging for prostate cancer detection - recommendations from a UK consensus meeting
- (2018) Mrishta Brizmohun Appayya et al. BJU INTERNATIONAL
- Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer
- (2018) Yi-Mi Wu et al. CELL
- Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer
- (2018) David A. Quigley et al. CELL
- TMPRSS2-ERG controls luminal epithelial lineage and antiandrogen sensitivity inPTENandTP53-mutated prostate cancer
- (2018) Alexandra M Blee et al. CLINICAL CANCER RESEARCH
- Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS)
- (2018) Rita Faria et al. EUROPEAN UROLOGY
- Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies
- (2018) Gwenaelle Gravis et al. EUROPEAN UROLOGY
- Screening for Prostate Cancer
- (2018) et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017
- (2018) Veda N. Giri et al. JOURNAL OF CLINICAL ONCOLOGY
- Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment
- (2018) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial
- (2018) Piet Ost et al. JOURNAL OF CLINICAL ONCOLOGY
- [ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
- (2018) Michael S Hofman et al. LANCET ONCOLOGY
- The Genomics of Prostate Cancer: emerging understanding with technologic advances
- (2018) Mark A Rubin et al. MODERN PATHOLOGY
- The long tail of oncogenic drivers in prostate cancer
- (2018) Joshua Armenia et al. NATURE GENETICS
- MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis
- (2018) Veeru Kasivisvanathan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)
- (2018) Edoardo Francini et al. PROSTATE
- Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial
- (2018) Liselotte M.S. Boevé et al. EUROPEAN UROLOGY
- Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial
- (2018) Fred Saad et al. LANCET ONCOLOGY
- Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer
- (2018) David A. Quigley et al. CELL
- Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study
- (2018) Marloes van der Leest et al. EUROPEAN UROLOGY
- Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer
- (2018) Daniel Nava Rodrigues et al. JOURNAL OF CLINICAL INVESTIGATION
- Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
- (2018) Spencer L James et al. LANCET
- Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories
- (2018) Kyle J Foreman et al. LANCET
- Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
- (2018) Christopher C Parker et al. LANCET
- Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study
- (2018) Olivier Rouvière et al. LANCET ONCOLOGY
- Radical Prostatectomy or Watchful Waiting in Prostate Cancer — 29-Year Follow-up
- (2018) Anna Bill-Axelson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade
- (2018) Wassim Abida et al. JAMA Oncology
- Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study
- (2017) Tomasz M. Beer et al. EUROPEAN UROLOGY
- Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations—A Report of a European School of Oncology Task Force
- (2017) Caroline M. Moore et al. EUROPEAN UROLOGY
- Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer
- (2017) W. James Morris et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
- (2017) Tomasz M. Beer et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial—FIRSTANA
- (2017) Stéphane Oudard et al. JOURNAL OF CLINICAL ONCOLOGY
- Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study
- (2017) Hashim U Ahmed et al. LANCET
- Genomic hallmarks of localized, non-indolent prostate cancer
- (2017) Michael Fraser et al. NATURE
- The inflammatory microenvironment and microbiome in prostate cancer development
- (2017) Karen S. Sfanos et al. Nature Reviews Urology
- Follow-up of Prostatectomy versus Observation for Early Prostate Cancer
- (2017) Timothy J. Wilt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
- (2017) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
- (2017) Nicholas D. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- SOX2 promotes lineage plasticity and antiandrogen resistance in TP53 - and RB1 -deficient prostate cancer
- (2017) Ping Mu et al. SCIENCE
- Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance
- (2017) Sheng Yu Ku et al. SCIENCE
- Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories
- (2017) Renea A. Taylor et al. Nature Communications
- Association between a 17-gene genomic prostate score and multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa)
- (2017) Michael S. Leapman et al. PLoS One
- PI-RADS Prostate Imaging – Reporting and Data System: 2015, Version 2
- (2016) Jeffrey C. Weinreb et al. EUROPEAN UROLOGY
- A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score
- (2016) Jonathan I. Epstein et al. EUROPEAN UROLOGY
- Prostate cancer
- (2016) Gerhardt Attard et al. LANCET
- Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study
- (2016) John W Yaxley et al. LANCET
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
- (2016) Nicholas D James et al. LANCET
- Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
- (2016) Himisha Beltran et al. NATURE MEDICINE
- Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer
- (2016) Jenny L. Donovan et al. NEW ENGLAND JOURNAL OF MEDICINE
- 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer
- (2016) Freddie C. Hamdy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
- (2016) Colin C. Pritchard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prostate epithelial cell of origin determines cancer differentiation state in an organoid transformation assay
- (2016) Jung Wook Park et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Integrative Clinical Genomics of Advanced Prostate Cancer
- (2015) Dan Robinson et al. CELL
- The Molecular Taxonomy of Primary Prostate Cancer
- (2015) Adam Abeshouse et al. CELL
- Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers
- (2015) A. M. Aparicio et al. CLINICAL CANCER RESEARCH
- Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening
- (2015) A. Auvinen et al. CLINICAL CANCER RESEARCH
- Cell types of origin for prostate cancer
- (2015) Suk Hyung Lee et al. CURRENT OPINION IN CELL BIOLOGY
- Impact of Bone-targeted Therapies in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Patients Treated with Abiraterone Acetate: Post Hoc Analysis of Study COU-AA-302
- (2015) Fred Saad et al. EUROPEAN UROLOGY
- Trends in Management for Patients With Localized Prostate Cancer, 1990-2013
- (2015) Matthew R. Cooperberg et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
- (2015) Charles J Ryan et al. LANCET ONCOLOGY
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
- (2015) Christopher J. Sweeney et al. NEW ENGLAND JOURNAL OF MEDICINE
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Radiotherapy Versus Wait-and-See After Radical Prostatectomy: 10-year Follow-up of the ARO 96–02/AUO AP 09/95 Trial
- (2014) Thomas Wiegel et al. EUROPEAN UROLOGY
- Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study
- (2014) Emilie Lalonde et al. LANCET ONCOLOGY
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- (2014) Eugene D Kwon et al. LANCET ONCOLOGY
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Copy number alteration burden predicts prostate cancer relapse
- (2014) H. Hieronymus et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Denosumab and Bone Metastasis–Free Survival in Men With Nonmetastatic Castration-Resistant Prostate Cancer: Exploratory Analyses by Baseline Prostate-Specific Antigen Doubling Time
- (2013) Matthew R. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- GermlineBRCAMutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer
- (2013) Elena Castro et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of prostate cancer in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013
- (2013) Scott Williams et al. LANCET ONCOLOGY
- The genetic epidemiology of prostate cancer and its clinical implications
- (2013) Rosalind Eeles et al. Nature Reviews Urology
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- ESUR prostate MR guidelines 2012
- (2012) Jelle O. Barentsz et al. EUROPEAN RADIOLOGY
- Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)
- (2012) Michel Bolla et al. LANCET
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
- (2012) Karim Fizazi et al. LANCET ONCOLOGY
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
- (2011) Brett S. Carver et al. CANCER CELL
- Duration of Short-Course Androgen Suppression Therapy and the Risk of Death As a Result of Prostate Cancer
- (2011) Anthony V. D'Amico et al. JOURNAL OF CLINICAL ONCOLOGY
- Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial
- (2011) Padraig Warde et al. LANCET
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
- (2011) Karim Fizazi et al. LANCET
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?
- (2009) Emilio Bria et al. CANCER
- Adjuvant hormone therapy for localised and locally advanced prostate carcinoma: A systematic review and meta-analysis of randomised trials
- (2009) M.D. Shelley et al. CANCER TREATMENT REVIEWS
- Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial
- (2009) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial
- (2009) Ian M. Thompson et al. JOURNAL OF UROLOGY
- Duration of Androgen Suppression in the Treatment of Prostate Cancer
- (2009) Michel Bolla et al. NEW ENGLAND JOURNAL OF MEDICINE
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
- Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial
- (2008) Anders Widmark et al. LANCET
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started